Non-Invasive, High-Resolution (¹H₂O) Metabolic Activity Diffusion Imaging [MADI] of Rat Glioma

Area of Science:

• Biomedical Imaging
• Neuro-oncology
• Metabolic Imaging

Background:

• Metabolic Activity Diffusion Imaging (MADI) is a novel diffusion-weighted MRI technique.
• MADI quantifies homeostatic cellular water efflux rate constant (k_io) without contrast agents.
• k_io reflects transmembrane water cycling linked to cellular energy utilization, serving as a metabolic biomarker.

Purpose of the Study:

• To evaluate MADI's utility in brain cancer detection and assessment.
• To compare MADI-derived metabolic parameters with ¹⁸FDG-PET in a rat brain tumor model.
• To assess MADI's response to temozolamide and radiation treatment.

Main Methods:

• MADI was applied to rats with syngeneic RG2 brain tumors and non-tumor-bearing controls at 11.75 T.
• MADI quantified k_io, cell volume (V), and cell density (ρ), enabling calculation of k_ioV and k_ioVρ.
• ¹⁸FDG-PET was used for comparison; a subset of rats received temozolamide and radiation therapy.

Main Results:

• Tumor k_ioV significantly decreased, while ¹⁸FDG-PET SUV_max increased compared to contralateral regions.
• Edematous peritumoral regions showed higher k_ioV than contralateral; k_io and k_ioVρ showed moderate increases.
• Treatment did not significantly alter tumor size, MADI parameters, or ¹⁸FDG-PET SUV_max; water-to-glucose uptake ratio suggested limited glycolysis contribution to energy production.

Conclusions:

• MADI provides novel cytometric and metabolic parameters for brain cancer detection and assessment.
• MADI offers a contrast-agent-free method to evaluate tumor metabolism and cellularity.
• Further research is warranted to explore MADI's clinical potential in neuro-oncology.